CRSP Q3 EPS Forecast Lifted by Brookline Capital Markets

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Brookline Capital Markets boosted their Q3 2026 EPS estimates for shares of CRISPR Therapeutics in a research report issued on Tuesday, August 4th. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn ($1.30) per share for the quarter, up from their prior estimate of ($1.31). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.90) per share. Brookline Capital Markets also issued estimates for CRISPR Therapeutics’ Q4 2026 earnings at ($1.87) EPS, FY2026 earnings at ($5.63) EPS and FY2027 earnings at ($4.51) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. The company had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, July 8th. Sanford C. Bernstein upped their price objective on CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Citigroup increased their price objective on CRISPR Therapeutics from $82.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday. Evercore reissued an “outperform” rating and set a $76.00 price objective on shares of CRISPR Therapeutics in a report on Monday, May 11th. Finally, Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the stock an “equal weight” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $68.82.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $52.45 on Thursday. CRISPR Therapeutics has a 52-week low of $44.12 and a 52-week high of $78.48. The company has a fifty day moving average of $52.52 and a 200-day moving average of $52.31. The company has a market capitalization of $5.07 billion, a P/E ratio of -11.02 and a beta of 1.74. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.96 and a current ratio of 17.85.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. GSK plc purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $168,890,000. Orbis Allan Gray Ltd grew its stake in shares of CRISPR Therapeutics by 76.9% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after buying an additional 1,201,600 shares during the last quarter. State Street Corp increased its position in CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after buying an additional 859,334 shares in the last quarter. ARK Investment Management LLC increased its position in CRISPR Therapeutics by 7.5% during the 4th quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock valued at $551,777,000 after buying an additional 735,084 shares in the last quarter. Finally, Norges Bank purchased a new position in CRISPR Therapeutics during the fourth quarter valued at $25,706,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity

In related news, insider Naimish Patel sold 3,786 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider directly owned 19,357 shares of the company’s stock, valued at $1,076,636.34. This represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by corporate insiders.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CRISPR Therapeutics reported second-quarter revenue above expectations and a narrower-than-expected loss, helped by growing CASGEVY sales across international markets and continued progress in clinical programs. CRISPR Therapeutics’ Q2 Earnings & Revenues Surpass Estimates
• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, indicating continued confidence in CRSP’s commercial opportunity and gene-editing pipeline. Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG
• Positive Sentiment: An investor analysis characterized CRSP as a “Strong Buy,” citing CASGEVY sales growth and the potential of the in-vivo editing program CTX310. CRISPR: Strong Buy CASGEVY Sales Growth and In Vivo Expansion With CTX310
• Neutral Sentiment: RBC described the second quarter as relatively quiet, with CASGEVY advancing commercially while investors await additional siRNA and pipeline data readouts. Crispr Therapeutics Posts Quiet Quarter as Casgevy Advances
• Negative Sentiment: Brookline Capital Markets lowered its Q4 2026 EPS estimate to a loss of $1.87 from $1.69 and reduced its FY2026 estimate to a loss of $5.63 from $5.36. The revisions reinforce expectations for substantial near-term losses.
• Negative Sentiment: Brookline also modestly cut its profitable long-range forecasts for FY2028, FY2029 and FY2030, although it raised its FY2027 estimate to a loss of $4.51 from $5.05. The overall changes suggest a slightly more cautious view of CRSP’s earnings ramp.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.